Crescent Biopharma advances CR-001 combos, clears IND for CR-002 and sets mid‑2027 data timelines
Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.
How this was made
The 30-second read
Why it matters
The FDA IND allowance for CR-002 and the start of CR-001 combination cohorts expand the company’s clinical execution path and push investors to reprice probability-weighted future readouts into 2026-2027.
Market read
Traders may adjust biotech risk exposure based on regulatory clearance and trial-start timing, even without new efficacy results in this article.
What to watch
Key risk is whether CR-001 combo signals translate into durable efficacy and tolerability, and whether CR-002’s ADC performance in APOLLO matches the mechanistic rationale; without new efficacy/safety datapoints, valuation support may be fragile.
Background
Crescent Biopharma is advancing an oncology pipeline with CR-001 chemo combinations and CR-002, a topoisomerase inhibitor ADC targeting PD-L1, plus a China-focused collaboration with Kelun-Biotech.
Ticker impact
Crescent Biopharma reports enrollment in CR-001 chemo combination cohorts, IND clearance for CR-002, and trial data timelines into 2027.
Likely upward bias as investors price forward the expanded Phase 1/2 pipeline and upcoming 2026-2027 data milestones.
The article is a first-report style update tied to FDA IND clearance and trial start timing, which typically improves near-term sentiment for development-stage biotechs, though the value depends on future efficacy/safety results.
Market effects
Adds incremental momentum to oncology ADC and chemo-combination development narratives, reinforcing investor focus on IND-cleared assets and near-term trial initiation schedules.
Limited direct regional impact, but the China partnership and trial activity can support cross-border biotech sentiment.
Moderate, as FDA IND clearance and global trial timelines are relevant to international oncology investors tracking ADC and PD-L1 targeting strategies.
Counterpoint
The update is largely timeline-based (mid-2027 and H2 2027 data), so near-term price may fade if investors view it as non-data and already-expected pipeline progression.
Key entities
- companyCrescent Biopharma, Inc.
Subject of the update, advancing CR-001 and CR-002 clinical programs and setting 2026-2027 timelines.
- regulatorFDA
Allowed the IND for CR-002, enabling the APOLLO Phase 1/2 trial to start.
- partnerKelun-Biotech
Partnering on multiple CR-001 plus ADC trials in China and holding exclusive rights to CR-003 outside Greater China.